Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on November 25, 2026 | For discussion with your oncologist

TRIAL

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

NCT ID: NCT05315258 Phase: PHASE2 Sponsor: University of Oxford Status: Active Not Recruiting

SUMMARY

Researchers are trying to find ways to improve the management of people with intermediate or high risk resected cutaneous melanoma or with primary uveal melanoma.

This research study is investigating using a new blood test to decide when to give a drug called tebentafusp. Tebentafusp has been used in clinical trials in patients with advanced cutaneous and uveal melanoma. This study is designed to determine if tebentafusp can help patients with cutaneous or uveal melanoma live longer.

KEY ELIGIBILITY CRITERIA

- A patient will be eligible for inclusion in cohort A or B if all of the following criteria apply:
- 1. Uveal or cutaneous melanoma with MRD detected in molecular screening, and repeat confirmation of MRD in the sample taken as part of screening for the main study.
- 2. Written (signed and dated) informed consent.
- 3. Male or female, Age 18 years and above.
- 4. Life expectancy of at least 3 months.
- 5. ECOG performance score of 0 or 1.
- 6. No evidence of metastatic disease on a CT scan of neck/thorax/abdomen/pelvis for cohorts A and B and also on MRI liver for uveal melanoma for cohort B.
- 7. Those receiving prior immunotherapy must have recovered from any immune-mediated adverse events (d grade 1) other than endocrinopathies on stable replacement therapy.
- 8. Haematological and biochemical indices within normal ranges (refer to protocol for ranges)
- A patient will not be eligible for tebentafusp administration if any of the following apply:

Total sites: 10 | 0 currently recruiting

This document is for informational purposes only and does not constitute medical advice. Always discuss clinical trial decisions with your oncologist. Data sourced from ClinicalTrials.gov (NCT05315258) and public sources. Generated by FindMyCure.ai.